Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Rhea-AI Summary

Anika Therapeutics, Inc. (NASDAQ: ANIK) will release its third quarter 2022 financial results after market close on November 8, 2022. The company will host a conference call on the same day at 5:00 p.m. ET to discuss these results and highlight business developments. Interested parties can join via phone or listen to a live audio webcast on Anika's Investor Relations webpage. Anika focuses on innovative orthopedic care, particularly in joint preservation, leveraging hyaluronic acid and implant solutions.

Positive

• Scheduled release of Q3 2022 financial results, indicating transparency and ongoing communication with investors.
• Focus on high opportunity spaces within orthopedics, potentially driving future growth.

Negative

• No specific financial metrics or guidance provided, leaving investors uncertain about performance.

BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tuesday, November 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-888-256-1007 (toll-free domestic) or 1-856-344-9221 (international) and providing the conference ID number 2205523. A live audio webcast will be available in the Investor Relations section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair and bone preserving joint technologies, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com

FAQ

When will Anika Therapeutics release its Q3 2022 financial results?

Anika Therapeutics will release its Q3 2022 financial results on November 8, 2022.

What time is the investor conference call for Anika's financial results?

The investor conference call will take place at 5:00 p.m. ET on November 8, 2022.

How can I access the live audio webcast for Anika's conference call?

The live audio webcast can be accessed through Anika's Investor Relations section on their website.

What is the focus of Anika Therapeutics in the orthopedic market?

Anika Therapeutics specializes in joint preservation and innovative solutions in orthopedic care.

What products does Anika Therapeutics offer?

Anika offers minimally invasive products for pain management, regenerative solutions, and joint preservation technologies.